Onpattro (patisiran) is a first-in-class treatment that slows down the progression of hereditary transthyretin amyloidosis (hATTR).
polyneuropathy
-
Posted: January 30, 2019Categories: Approvals
Onpattro (patisiran) is a first-in-class treatment that slows down the progression of hereditary transthyretin amyloidosis (hATTR).